Current knowledge on the genetic background of developmental dysplasia of the hip and the histomorphological status of the cartilage

Developmental dysplasia of the hip (DDH) represents a morphological abnormality characterized by the incongruity of femoral head and acetabulum. It ranges from mild dysplastic changes to complete dislocation. DDH has been associated with several hereditary and environmental risk factors, which could explain the incidence variability among different countries. Numerous genes may be involved in the disease etiology and progression. However, there are controversies in the literature regarding some of these genes. DDH-induced secondary osteoarthritis (OA) is characterized by changes in the macromolecule content of the cartilage and the expression of cartilage degradation markers. In addition, it exhibits a pattern of specific histological changes, with several reported differences between primary and DDH-induced secondary OA. The articular cartilage of patients with DDH shows specific radiological characteristics, including changes visible already in infancy, but also at pre-arthritic stages, early stages of OA, and in fully developed DDH-induced secondary OA. Although DDH has been extensively researched in different disease stages, the etiology of the disorder still remains uncertain. This review focuses on the current knowledge on the histomorphological status of the cartilage and the genetic background of DDH.
Developmental dysplasia of the hip (DDH) is a pathological condition characterized by the incongruity of the femoral head and acetabulum. It encompasses a wide range of conditions, from mild dysplastic changes to complete dislocation (1). There is still no universally agreed definition of DDH, but the most frequently used ones are the anatomic definition, which defines DDH as abnormal development of the articulating bones of the hip, and radiological definition, which defines DDH as a structural abnormality of the acetabulum or femoral head with continuous Shenton’s line. In the same manner, subluxation is defined as structural abnormalities and discontinuation of Shenton’s line, and luxation as an abnormality without contact between the femur and acetabulum (2). The hip joint space forms in the 7th-8th week of gestation by autolytic degeneration, and the hip joint basic morphology is developed by the end of week 10. Only after this point can dislocation occur (3). In DDH, the acetabulum is altered both in form and orientation, with physiological width but with increased length and decreased depth, thus insufficiently covering the femoral head. The femoral head is usually aspherical and has increased anteversion, together with a coxa valga deformity. The insufficient coverage over the femoral head, the hip center of rotation lateralization, and a smaller contact area may lead to asymmetric dispersion of forces in the hip. This results in increased mechanical stress on the cartilage beyond the level of physiological tolerance and leads to the development of cartilage lesions and secondary osteoarthritis (OA) (4,5). Patients with untreated DDH may often require total hip replacement, for which many efficient approaches have been described (6-10).

Several hereditary and environmental factors have been associated with DDH, and these may explain the incidence variability among different countries (11). The risk factors for DDH include being firstborn, female sex, breech birth, presence of oligohydramnios, positive family history, joint laxity, swaddling, etc (12). According to Barlow (13), 1 in 60 newborns have hip instability, and more than 60% of them stabilize in the first week without any treatment, while 88% stabilize within the first two months. The remaining 12% have DDH that will persist without therapy. The risk for a child to develop DDH is 6% if one of his or her siblings has DDH, 12% if one of his or her parents has DDH, and 36% if both a parent and a sibling have DDH (14). Canadian indigenous people who in their childhood were swaddled on a cradleboard had 10 times higher incidence of DDH (15). The etiology of DDH still remains uncertain, which is why we reviewed the current knowledge on the histomorphological status of the cartilage and on the genetic background of DDH.

GENETICS AND TRANSCRIPTOMICS

There are two groups of patients with DDH: a) the group with acetabular dysplasia caused by a large number of gene variations, usually diagnosed later in life, and b) the group with generalized soft tissue and joint laxity, usually diagnosed in the neonatal period, when hip dislocation occurs (14). Each gene involved in DDH pathophysiology has a modest effect, thus making the identification of such genes a challenge (16). This may explain the contradictory results of genetic association-based studies of DDH (17). Studies identified several genes that may contribute to the DDH etiology (Table 1) (18-32). However, other authors showed no association between certain single nucleotide polymorphisms or genes and DDH (Table 2) (33-36). These contradictory results may be explained by the population-specificity of the detected genes and single nucleotide polymorphisms. Therefore, these results should not be used as a basis for causal inference and indicate the need for thorough population-specific studies.

A recent study, performed on samples taken from the external portion of the femoral head-neck junction, assessed the association between DDH and metabolic disorders of the cartilage in DDH patients, patients with primary OA, and patients with femoral neck fracture (FNF). DDH patients had lower mRNA expression of collagen type II and aggrecan compared with other groups. Furthermore, they had higher mRNA expression of collagen type X and matrix metalloproteinase-13 (MMP-13), as cartilage degradation markers, than the FNF group, but the expression did not differ from the OA group. The authors concluded that the DDH group had more impaired cartilage metabolism than the OA group. MMP-13 is responsible for the degradation of collagen type II and other collagens (37) and MMP-13 in human chondrocytes was reported to be decreased by growth differentiation factor-5 (GDF-5) (38), which might explain a part of the DDH cascade.

Aki et al (18) compared the whole-genome chondrocyte transcriptomics in Japanese patients with DDH-associated secondary OA and FNF with that of Caucasian patients suffering from primary hip OA, whose data were available in the literature. The cartilage specimens of patients with secondary OA were obtained from a location on the femoral head adjacent to the weight-bearing area, while the specimens of FNF patients were obtained...
TABLE 1. Studies of genetic background of developmental dysplasia of the hip (DDH) showing correlation between genes and the disease in different populations∗

| Locus | Gene | Protein | Function | Population | Correlation to DDH | Reference |
|-------|------|---------|----------|------------|---------------------|-----------|
| 1q24  | dermatopontin | dermatopontin | role in angiogenesis, fetal development, wound healing, tumor metastasis; increased expression in MSCs in chondrogenic differentiation | Japanese | overexpressed in DDH OA | (18) |
| 1q32  | ATPase plasma membrane Ca2+ transporting 4 (ATP2B4) | ATPase 2B4 | regulation of bone homeostasis | Saudi Arabian | interaction between rare heterozygous variants of HSPG2 and ATP2B4 genes (19) is connected to DDH in a studied family due to a combined effect of both variants; one member was asymptomatic, which suggests incomplete penetration of this variant | |
| 1p36  | heparan sulfate proteoglycan 2 (HSPG2) | perlecan | proteoglycan that cross-links extracellular matrix components and cell-surface molecules important in musculoskeletal development | Caucasian | | |
| 4q12  | insulin-like growth factor-binding protein 7 (IGFBP7) | insulin-like growth factor-binding protein 7 | development of cartilage, muscles and bone during prenatal and infantile growth periods | Japanese | overexpressed in DDH OA | (18) |
| 4q34-35 | teneurin transmembrane protein 3 (TENM3) | teneurin transmembrane protein 3 | multifunction transmembrane protein involved in signal transduction in developing limb and expressed in prechondrogenic mesenchymal cells | Caucasian | mutation discovered in a multigeneration DDH-affected family | (20) |
| 4q13 | CX3-C motif chemokine receptor 1 (CXCRI) | CX3-C motif chemokine receptor 1 | mediates cellular adhesive and migratory functions and is expressed in MSCs destined to become chondrocytes | Caucasian | mutation with a deleterious effect found in 4 generations, 72 family members affected by DDH | (21) |
| 6q25 | estrogen receptor 1 (ESR1) | Estrogen receptor 1 | regulates transcriptional responses | Caucasian | possible correlation of gene polymorphism to DDH | (22) |
| 9q22 | asporin (ASPN) | asporin | extracellular matrix protein that can bind to TGF-β1 and sequentially inhibit TGF-β5/Smad signaling | Han Chinese | possible correlation of gene polymorphism to DDH | (23) |
| 12q | vitamin D receptor (VDR) | vitamin D receptor | regulates transcriptional responses | Caucasian | possible link between some haplotypes and the risk of severe OA in patients with DDH | (24) |
| 1q22 | collagen type II alpha 1 chain | collagen type II alpha 1 chain | involved in collagen type II synthesis | Caucasian | possible link between some haplotypes and the risk of severe OA in patients with DDH | (25) |
| 17q21 | homeobox (HOX) genes cluster | / | developmental regulatory system providing cells with specific positional identities along the developing joint and spine | Japanese | autosomal dominant inheritance with a considerably consistent phenotype | (26) |
| 17q21 | homeobox 89 (HOXB9) | homeobox 89 | involved in embryonic limb developments | Chinese | may be susceptibility gene | (27) |
| 17q21-q2 | collagen type II alpha 1 chain | collagen type II alpha 1 chain | involved in collagen type II synthesis | Chinese | may be susceptibility gene for DDH | (27) |
| 17q23 | pregnancy-associated plasma protein-A2 (PAPPA2) | pregnancy-associated plasma protein-A2 | regulates IGF release and effect, important for the development of the fetus and normal postnatal growth | Han Chinese | single SNP associated with sporadic DDH | (28) |
| 17q23 | T-box transcription factor 4 (TBX4) | T-box transcription factor 4 | transcription factor involved in formation of posterior mesoderm and axial development | Han Chinese | one SNP associated with DDH in both genders, one SNP only in male patients | (29) |
| 19p13 | Krüppel-like Factor 2 (KLF2) | Krüppel-like Factor 2 | potential regulator of expression of MMPs | Japanese | overexpressed in DDH OA | (18) |
| 20q11 | growth differentiation factor 5 (GDF5) | growth differentiation factor 5 | a member of TGF-β superfamily, closely related to BMP subfamily, key role in osteogenesis, chondrogenesis and joint formation | Han Chinese | single functional SNP associated with DDH | (30) |
| 20q11 | GDF5 promoter | / | / | Han Chinese | two SNPs associated with DDH in female population | (31) |
| 20q11 | / | / | / | Caucasian | two SNPs associated with DDH in Caucasian population | (17) |

∗MSCs – mesenchymal stem cells; OA – osteoarthritis; ATP – adenosine triphosphate; TGF – transforming growth factor; KGF – insulin-like growth factor; SNP – single nucleotide polymorphism; MMP – matrix metalloproteinase; BMP – bone morphogenetic proteins.
from the inner and intact, non-weight bearing area of the femoral head. The study found 888 up-regulated and 732 down-regulated genes in DDH-induced secondary OA patients in comparison with FNF patients. The authors also reported that 90% of up-regulated genes in primary OA were different from those in DDH-induced secondary OA. Furthermore, DDH-induced secondary OA samples had high dermatopontin (DPT), insulin-like growth factor-binding protein 7 (IGFBP7), and Krüppel-like factor 2 (KLF2) expression (18). DPT is a protein of the extracellular matrix (ECM) that interacts with transforming growth factor β1 (TGF-β1) and decorin, inhibiting the formation of decorin-TGF-β1 complex, thus enhancing the effect of TGF-β1 (39). TGF-β1 plays a role in bone remodeling, parenchymal fibrosis, blood vessel formation, fetal growth, wound healing, and other pleiotropic roles in prenatal development and postnatal life (known role in cancer, inflammation, etc) (18,40,41). IGFBPs are a part of the insulin growth factor-1 (IGF-1) metabolic pathway (42). IGF-1 induces mesenchymal to osteoblast differentiation and is highly expressed in the bone matrix, having a crucial role in bone formation (43). It circulates in the blood and then binds to IGFBPs, which control the distribution and activity of the IGF-1 with its receptors. IGFBP7 suppresses osteoclastogenesis and supports osteogenic differentiation of bone marrow-derived mesenchymal stem cells (42). IGFBPs are processed by the bone morphogenetic protein-1 (BMP-1) metalloproteinase, which also releases BMP-2 and BMP-4 from their latent complexes (44). Both of these molecules play an essential role in osteogenesis and chondrogenesis and could be important in DDH development (45). KLF2 inhibits macrophage and endothelial activation in inflammation, as well as regulates cartilage degeneration by inhibiting MMP-13 expression, thus regulating the cleavage of collagen type II (18,46). Surprisingly, Aki et al showed an up-regulation of KLF2 expression in secondary DDH-associated OA, while previous studies showed KLF2 down-regulation in OA patients (18,46). The authors contribute this difference to a different OA stage in their patients (18). However, in our opinion, this finding needs further clarification.

HISTOLOGY OF THE ARTICULAR CARTILAGE IN DDH

The DDH-affected acetabular and femoral cartilage show similar histological changes. These changes are most noticeable in the iliac acetabular growth plate, where irregularly arranged chondrocytes are observed, shrunken at some places and enlarged at others, showing a tendency for degeneration. In the femoral head, dysmorphic chondrocytes are visible, which aggregate in some areas and are absent in others (47,48). In DDH-affected hips, the acetabular articular cartilage is thicker than in healthy hips (Figure 1). This phenomenon can be observed already during infancy and is used as a sign in the early diagnosis of DDH (49,50). Cartilage collagenous fibrils in DDH are rare and disorganized, similar to decreased and scattered fibrils in OA patients.

Histological analysis has shown that the chondrocyte count in the articular cartilage is significantly decreased in primary OA, while, interestingly, it is not affected in DDH patients.

**TABLE 2.** Studies of genetic background of developmental dysplasia of the hip (DDH) showing no correlation between investigated genes and the disease in different populations*

| Locus | Gene          | Protein                  | Function                  | Population | Correlation to DDH                                                                 | Reference |
|-------|---------------|--------------------------|---------------------------|------------|----------------------------------------------------------------------------------|-----------|
|       | collagen type II alpha I chain (COL2A1) | collagen type II alpha I chain | involved in collagen type II synthesis | Caucasian | although variants in these genes may contribute to the development of OA in DDH patients, they do not contribute to DDH | (33)      |
|       | vitamin D receptor (VDR) | vitamin D receptor | regulates transcriptional responses | Caucasian | no significant association between 4 SNPs and DDH | (34)      |
|       | collagen type I alpha I chain (COL1A1) | collagen type I alpha I chain | involved in collagen type I synthesis | Chinese | polymorphisms of PCOL2 (in promoter) and Sp1 (in intron I) binding sites in COL1A1 gene may not be the major susceptibility genes of DDH | (35)      |
|       | homeobox B9 (HOXB9) | homeobox B9 | involved in embryonic limb developments | Caucasian | no significant association between 8 SNPs and DDH | (36)      |

*OA – osteoarthritis; SNP – single nucleotide polymorphism.
FIGURE 1. Normal articular cartilage and articular cartilage in developmental dysplasia of the hip (DDH) at different stages of osteoarthritis (OA). (A) Normal articular cartilage. The cartilage surface is smooth, chondrocytes and collagenous fibrils are organized into the superficial, middle, and deep zone. A tidemark clearly separates the deep from the calcified zone. Proteoglycans are present in all three cartilage zones. The subchondral bone plate and the trabeculae are thin. (B) Non-OA DDH. The cartilage surface is smooth, cartilage thickness is increased, and chondrocyte count is high. Collagenous fibrils are rare compared with normal cartilage. (C) Early-stage primary OA. The cartilage surface is intact, but superficial fibrillation is visible at some regions of the surface. Chondrocytes and collagenous fibrils are organized, but are fewer in number. Non-viable cells are visible, especially in the superficial zone. The color fading in the upper third of the cartilage indicates the loss of proteoglycans. Bone trabeculae are thicker. (D) Early-stage DDH-induced secondary OA. The cartilage surface is smooth. Total cell count is unchanged, but the incidence of cell death is high, especially in the superficial zone. Collagenous fibrils are rare in comparison with normal cartilage. Some proteoglycan loss is visible at the upper third of the cartilage. (E) Late-stage primary OA. The cartilage surface is eroded and fibrillated. The chondrocyte count and the number of viable cells are significantly decreased. Chondrocytes form aggregates, while collagenous fibrils are rare and disorganized. The tidemark area is significantly increased. The loss of color indicates a decrease in total proteoglycan content. The subchondral bone plate and trabeculae are thicker. (F) Late-stage DDH-induced secondary OA. The cartilage surface is fibrillated and eroded. There are a few viable chondrocytes, which are shrunken at some places and enlarged at others. Chondrocytes are irregularly organized, aggregating in some regions, while being absent in others. Collagenous fibrils are rare and without any structure. A significant loss of proteoglycans is present. SZ – superficial zone; IZ – intermediate (middle) zone; DZ – deep zone; asterisk – tidemark; CZ – calcified zone; SB – subchondral zone.
Some characteristics of DDH-induced secondary OA are not typical for primary OA. In primary OA, the weight-bearing regions of the femur exhibit a higher degree of cartilage degradation, while the cartilage in the non-weight bearing regions is usually still healthy or shows only early signs of degenerative changes. However, in DDH, the non-weight bearing region also shows various degrees of erosion. Early-stage OA in DDH patients is characterized by fully thick cartilage with a smooth surface and insignificant loss of proteoglycans. The chondrocyte density is high, but so is the occurrence of cell death, especially in the superficial zone – which is not typically observed in the early stages of primary OA. The remaining cells are metabolically highly active. As shown by immunostaining for proteases, a vast majority of viable chondrocytes produce a proteolytic enzyme (i.e., MMP-3 or MMP-9), thus contributing to the matrix and cartilage degradation. More advanced OA stages in DDH patients are accompanied by a more significant proteoglycan loss, especially in the surface regions. The cartilage surface is fibrillated with a small number of viable cells, which produce proteases (MMP-3, MMP-9, MMP-13, ADAMTS-4) (51).

OA changes are associated with the changes in the abundance of major ECM macromolecules, primarily collagen type II, aggrecan, and cartilage degradation markers (52). The content of collagen type II decreases with the progression of cartilage degradation, meaning that primary OA-affected cartilage has lower collagen type II levels than healthy cartilage. As expected, DDH-induced secondary OA cartilage also has decreased collagen type II content, which is even more pronounced in comparison with the primary OA group. Another indicator of cartilage degradation is decreased aggrecan levels in the cartilage matrix, which are lower in DDH-induced secondary OA than in healthy cartilage and primary OA-affected cartilage (37).

The most important cartilage degradation markers are collagen type X, MMPs, and keratan sulfate (KS) (37,53,54). Collagen type X is particularly expressed in hypertrophic chondrocytes and constitutes approximately 1% of the total amount of collagen in normal cartilage. Its expression is increased in degenerative joint diseases, such as OA (55). Collagen type X content is significantly higher in DDH-induced secondary OA tissue than in healthy cartilage and is similar to that in primary OA cartilage (37).

MMPs are the enzymes responsible for most of the proteolytic reactions associated with OA, with low expression in healthy cartilage. Based on their substrate specificity, they are divided into several groups, the most important being collagenases, disintegrin, and metalloproteinases with thrombospondin motifs (ADAMTSs) (52). Their levels increase with advanced degradation caused by either primary or DDH-induced secondary OA, and this increase explains the loss of collagen type II in DDH (37). So far, there has been little information on the difference between DDH-induced and primary OA cartilage tissue in MMP protein content. Some studies on DNA methylation and gene silencing have confirmed the differences in MMP-13 expression levels between the conditions, indicating a possible difference in total MMP-13 protein content (51). However, other studies found no such difference (37). Due to the scarcity of these studies, the results are inconclusive and further research is warranted.

ADAMTSs are a group of metabolically active metalloproteinases involved in various developmental and homeostatic processes (i.e., fertilization, cartilage metabolism, intravascular coagulation, von Willebrand factor activation) (56). Nineteen ADAMTS enzymes have been described (57). Some of them play a crucial role in cartilage degradation as they act as aggrecanases, characterized by enzymatic cleavage at the Glu373-Ala374 peptide bond of the aggrecan (56). The first two described aggrecanases are ADAMTS-4 and ADAMTS-5. ADAMTS-4 is induced as a response to numerous inflammatory cytokines, i.e., TGF-β, TNF-α, and IL-1β, while ADAMTS-5 is found in human cartilage in homeostasis and is essential for balancing between aggrecan catabolism and anabolism (58,59). Their expression profiles have so far been studied in primary OA, with an increased expression indicating degenerative processes and correlating with aggrecan loss and disease progression (59). However, it is still unclear whether the altered ADAMTSs expression is directly responsible for the disease pathogenesis or it is only a consequence of homeostasis imbalance (45). As with the other cartilage degradation markers, there is limited information on ADAMTSs expression in DDH-induced secondary OA tissue, but the same ADAMTS-4 content has been found in both DDH-induced and primary OA tissue (51). Moreover, ADAMTS-4 can degrade other constitutive molecules in the ECM of the human cartilage, such as cartilage oligomeric matrix protein, hyalectan, decorin, brevican, fibromodulin, etc. Therefore, ADAMTS-4 shows a broader proteolytic role in the metabolism, which should be addressed in terms of involvement in DDH-induced secondary OA pathogenesis (60).

Some of the other noteworthy biomarkers are MMP-3 and KS. Even though both MMP-3 and KS serve as
markers of cartilage degradation, and their expression increases with arthritic changes, there is no notable difference in their levels in early and advanced stages of DDH-induced secondary OA (53).

**RADIOLOGICAL CHARACTERISTICS OF THE ARTICULAR CARTILAGE IN DDH**

An ultrasound study showed an average acetabular cartilage thickness of 2.6 mm in healthy infants and of 4.6 mm in infants with DDH (49). A magnetic resonance imaging (MRI) study also reported that dysplastic hips cartilage was thicker than that of normal hips (1.77 mm vs 1.34 mm), which correlates with histological findings (61). Both groups showed an increased thickness in the superior lateral area, but in dysplastic hips the increase was significant (61). Another study reported that dysplastic hips without cartilage wear had relatively thicker acetabular cartilage in the anterosuperior area than healthy hips, while both groups had similar femoral cartilage thickness (62). In dysplastic hips, the acetabular edge was thickened, being either inverted or everted (63).

In 88 children with unilateral DDH, acetabular depth (AD) in the affected hip was significantly smaller compared with that in the contralateral unaffected hip. Also, with increased age, AD increase on the affected side was significantly smaller compared with that on the contralateral side (64). In children younger than three years with untreated DDH, the floor of the articular portion of the acetabulum advanced laterally, as evidenced by the thickening of the bony acetabulum portion immediately superior to the transitional zone (63). Also, the bony acetabulum lost sphericity in the anterior, superior, and posterior parts. Anterior and posterior acetabular rims were rotated toward each other, producing a reduced acetabular diameter (65).

Lateral acetabular coverage correlates with femoracetabular cartilage thickness, which indicates that the cartilage may transform under certain circumstances. In dysplastic hips, the cartilage at the lateral part was 35% thicker compared with the hips with normal acetabular coverage, suggesting that the hip morphologically changes in response to abnormal joint loading (65). One study showed a more prominent T2 signal decrease in the outer superficial ac- cartilage of dysplastic hips during weight loading in comparison with normal hips. This finding may be explained by changes in ECM and water distribution caused by abnormal weight bearing forces in DDH patients (66). In addition, we assume that these changes correlate with the histological evidence of lower proteoglycans content in DDH articular cartilage in comparison with healthy articular cartilage, which indirectly alters the water content in the cartilage.

Jessel et al (67) compared 96 symptomatic dysplastic hips of 74 DDH patients with the hips of healthy volunteers. The mean delayed gadolinium-enhanced MRI of cartilage (dGEMRIC) index for DDH patients with hip symptoms was 473 ± 104 msec, while the value for healthy volunteers was 570 ± 90 msec, suggesting a decrease in proteoglycans in symptomatic pre-OA DDH patients (67). Another study correlated dGEMRIC index of the weight bearing cartilage in DDH patients with dysplasia severity and pain, suggesting that dGEMRIC index might indicate early OA before radiographic changes are present (68). Arthroscopic and imaging studies showed that cartilage erosions in pre-OA DDH patients are usually located in the anterior superior part of the acetabulum, most commonly in the transitional zone between the cartilage and labrum (69-71).

In the early stages of DDH-induced secondary OA, T2 signal intensity in the superior acetabular cartilage was higher in comparison with normal hips, probably as a result of increased fluid amount and mobility, as well as of a loss of proteoglycans and disintegration of collagen network (72). DDH patients with total dGEMRIC index above 500 msec, ie, pre-OA DDH patients, had increased T1 values in the weight bearing area of the acetabulum, with lower values in peripheral regions compared with central regions. Patients with total dGEMRIC index below 500 msec, ie, DDH-induced secondary OA patients, had generally decreased T1 values, with no significant difference between central and peripheral regions (73).

In secondary DDH-associated OA, the cartilage thinned with disease progression. Due to the cartilage thinning, in approximately 80% of patients, a transition of the femoral head to an anterior and superior position was observed (74). Xu et al (75) studied dGEMRIC indices in different stages of DDH-induced secondary OA. Mild radiographic DDH-induced secondary OA patients showed a decline in chondral function from anterior-superior toward the superior region, while moderate and severe radiographic DDH-induced secondary OA patients exhibited global chondral dysfunction (75).

Delayed gadolinium-enhanced MRI of cartilage index values of the cartilage surrounding focal chondral erosions were lower in DDH hips than in the normal cartilage, sug-
gesting that the chondral erosions occur in combination with a global loss of proteoglycans. This indicates that DDH patients suffer not localized, but generalized, chondral damage (76). This observation may be related to the finding that DDH hips have more metabolically active chondrocytes that produce enzymes causing cartilage degradation. Furthermore, Hingsammer et al (77) state that patients with early radiographic OA may have localized chondral lesions, while biochemical changes (measured by dGEMRIC index) of the cartilage are present in the joint, although mechanical forces affecting the cartilage are asymmetric and localized. According to the authors, these data suggest that OA development in DDH may be induced by mechanical forces; however, there is certainly a biologic factor involved (77).

CONCLUSION

The current knowledge on DDH is comprehensive in terms of early screening and treatment. However, data on etiology and morphology behind DDH and DDH-induced secondary OA are scarce. In this review, we highlighted some of the molecules with a potentially crucial role in DDH and DDH-induced secondary OA pathogenesis that merit further investigation. In addition, as some genetically pre-determined articular surfaces do not articulate in DDH, while surfaces without a genetic predisposition articulate, we believe the hip joint requires further regional morphological characterization.

Funding This work was supported by the Croatian Science Foundation grant No. IP-2018-01-3688 "Acetabular and Femoral Cartilage Characterization in Adult Patients with Developmental Dysplasia of the Hip".

Ethical approval Not required.

Declaration of authorship IB, TS, and DD conceived and designed the study; TS, TS, and DD analyzed and interpreted the data; IB, TS, and DD drafted the manuscript. IB, TS, and DD critically revised the manuscript for important intellectual content; all authors gave approval of the version to be submitted; all authors agree to be accountable for all aspects of the work.

Competing interests All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.

References

1. Doyle SM, Bowen JR. Types of persistent dysplasia in congenital dislocation of the hip. 1996;65:266-76.
2. Connolly P, Weinstein SL. The natural history of acetabular development in developmental dysplasia of the hip. Acta Orthop Traumatól Turch. 2007;41 Suppl 1:1-5. [In Turkish] Medline:17483616
3. Ferrer-Torrellas M, Ceballos T, Ferrer-Loewinsohn A. Development of the hip joint in relation to congenital dislocation. Acta Orthop Belg. 1990;56:1 Pt A:13-22. Medline:2382537
4. Gala L, Clohisy JC, Beaulé PE. Hip dysplasia in the young adult. J Bone Joint Surg Am. 2016;98:63-73. Medline:26738905 doi:10.2106/JBJS.O.00109
5. Wiberg S. Studies on dysplastic acetabula and congenital subluxation of the hip joint. With special reference to the complication of coxarthrosis. Acta Chir Scand. 1939;83:28-38.
6. Delimar D, Cicak N, Klobucar H, Pecina M, Korzinek K. Acetabular roof reconstruction with pedicled iliac graft. Int Orthop. 2002;26:344-8. Medline:12466866 doi:10.1007/s00264-002-0381-1
7. Delimar D, Bicanic G, Pecina M, Korzinek K. Acetabular roof reconstruction with pedicled iliac graft: early clinical experience. Int Orthop. 2004;28:319-20. Medline:15057487 doi:10.1007/s00264-004-0555-0
8. Delimar D, Bohacek I, Pecina M, Bicanic G. Acetabular roof reconstruction with pedicled iliac graft: ten years later. Int Orthop. 2014;38:199-201. Medline:24248271 doi:10.1007/s00264-013-2170-4
9. Bicanic G, Delimar D, Delimar M, Pecina M. Influence of the acetabular cup position on hip load during arthroplasty in hip dysplasia. Int Orthop. 2009;33:397-402. Medline:19015852 doi:10.1007/s00264-008-0683-z
10. Bicanic G, Barbaric K, Bohacek I, Aljinovic A, Delimar D. Current concept in dysplastic hip arthroplasty: Techniques for acetabular and femoral reconstruction. World J Orthop. 2014;5:412-24. Medline:25232518 doi:10.5312/wjo.v5.i4.412
11. Paton RW, Choudry Q. Developmental dysplasia of the hip (DDH): diagnosis and treatment. Orthop Trauma. 2016;30:453-60. doi:10.1016/j.jorthpr.2016.05.015
12. LeVeau BF, Bernhardt DB. Developmental biomechanics: effect of forces on the growth, development, and maintenance of the human body. Phys Ther. 1984;64:1874-82. Medline:6505032 doi:10.1093/ptj/64.12.1874
13. Barlow TG. Early diagnosis and treatment of congenital dislocation of the hip. J Bone Joint Surg Br. 1962;44:292-301. doi:10.1302/0301-620X.44B2.292
14. Wynne-Davies R. Acetabular dysplasia and familial joint laxity: two etiological factors in congenital dislocation of the hip: a review of 589 patients and their families. J Bone Joint Surg Br. 1970;52:704-16. Medline:5487570 doi:10.1302/0301-620X.52B4.5284.704
15. Salter RB. Etiology, pathogenesis and possible prevention of congenital dislocation of the hip. CMAJ. 1968;98:933-45. Medline:5690507
16. Hogervorst T, Eilander W, Fikkers JT, Meulenbelt I. Hip ontogenesis: how evolution, genes, and load history shape hip morphotype and cartilotype. Clin Orthop Relat Res. 2012;470:3284-96. Medline:22926490 doi:10.1007/s11999-012-2511-4
Feldman G, Dalsey C, Fertala K, Azimi D, Fortina P, Devoto M, et al. Evidence of association between GDF5 polymorphisms and congenital dislocation of the hip in a Caucasian population. Osteoarthritis Cartilage. 2010;18:1144-9. doi:10.1016/j.joca.2010.05.018

Aki T, Hashimoto K, Ogasawara M, Itoi E. A whole-genome transcriptome analysis of articular chondrocytes in secondary osteoarthritis of the hip. PLoS One. 2018;13:e0199734. doi:10.1371/journal.pone.0199734

Basit S, Albalawi AM, Alharby E, Khoshhal KI. Exome sequencing identified rare variants in genes HSPG2 and ATP2B4 in a family segregating developmental dysplasia of the hip. BMC Med Genet. 2017;18:34. doi:10.1186/s12881-017-0393-8

Feldman G, Kappe D, Mookerjee-Basu J, Freeman T, Fertala A, Parvizi J. Novel mutation in Teneurin 3 found to cosegregate in all affecteds in a multi-generation family with developmental dysplasia of the hip. J Orthop Res. 2019;37:171-80. doi:10.1002/jor.24148

Feldman GJ, Parvizi J, Levenstien M, Scott K, Erickson JA, Fortina P, et al. Developmental dysplasia of the hip: linkage mapping and whole exome sequencing identify a shared variant in CXCR1 in all affected members of a large multigeneration family. J Bone Miner Res. 2013;28:2540-9. doi:10.1002/jbmr.1999

Kapoor B, Dunlop C, Wynn-Jones C, Fryer AA, Strange RC, Maffulli N. Vitamin D and oestrogen receptor polymorphisms in congenital dislocation of the hip and primary protrusio acetabuli – a preliminary study. J Negat Results Biomed. 2007;6:7. doi:10.1186/1477-5751-6-7

Shi D, Dai J, Zhu P, Qin J, Zhu L, Zhu H, et al. Association of the D repeat polymorphism in the ASPN gene with developmental dysplasia of the hip: a case-control study in Han Chinese. Arthritis Res Ther. 2008;10:R126. doi:10.1186/ar254

Jia J, Li L, Zhao Q, Zhang L, Ru J, Liu X, et al. Association of a single nucleotide polymorphism in pregnancy-associated plasma protein-A2 with developmental dysplasia of the hip: a case-control study. Osteoarthritis Cartilage. 2012;20:60-3. doi:10.1016/j.joca.2011.10.004

Wang K, Shi D, Zhu P, Dai J, Zhu L, Zhu H, et al. Association of a single nucleotide polymorphism in Tbx4 with developmental dysplasia of the hip: a case-control study. Osteoarthritis Cartilage. 2010;18:1592-9. doi:10.1016/j.joca.2010.09.008

Dai J, Shi D, Zhu P, Qin J, Ni H, Xu Y, et al. Association of a single nucleotide polymorphism in growth differentiate factor 5 with congenital dysplasia of the hip: a case-control study. Arthritis Res Ther. 2008;10:R126. doi:10.1186/ar254

Zhao L, Pan H, Wang J, Cheng Z, Cheng L, Wang B, et al. Two single nucleotide polymorphisms in the GDF5 gene are associated with development dysplasia of the hip in Chinese female population. Sci China Life Sci. 2013;56:1063-5. doi:10.1007/s11427-013-4514-0

Baghdadi T, Nejadhosseinian M, Shirkoori R, Mostafavi Tabatabaei R, Tamehri SS, Saffari M, et al. DNA hypermethylation of GDF5 in developmental dysplasia of the hip (DDH). Mol Genet Genomic Med. 2019;7:e887. doi:10.1002/mgg3.887

Rubini M, Cavallaro A, Calzolari E, Bighetti G, Sollazzo V. Exclusion of COL2A1 and VDR as developmental dysplasia of the hip genes. Clin Orthop Relat Res. 2008;466:878-83. doi:10.1007/s11999-008-0120-z

Jawadi AH, Wakeel A, Tamimi W, Nasr A, Iqbal Z, Mashhour A, et al. Association analysis between four vitamin D receptor gene polymorphisms and developmental dysplasia of the hip. J Genet. 2018;97:925-30. doi:10.1002/jgen.20141-018-0984-y

Jiang J, Ma H, Li Q, Lu J, Niu G, Zhang L, et al. Association analysis on the polymorphisms of PCOL2 and Sp1 binding sites of COL1A1 gene and the congenital dislocation of the hip in Chinese population. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2005;22:327-9. doi:10.1002/mgg3.88

Rouault K, Scotet V, Autret S, Gaucher F, Dubrana F, Tanguy D, et al. The Otto Aufranc Award: Identification of a 4 Mb region on chromosome 13q21 linked to developmental dysplasia of the hip in one 18-member, multigeneration family. Clin Orthop Relat Res. 2010;468:337-44. doi:10.1007/11999-009-1073-6

Jiang J, Ma H, Lu Y, Wang Y, Wang Y, Li Q, et al. Transmission disequilibrium test for congenital dislocation of the hip and HOXB9 gene or COL1A1 gene. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2003;20:193-5. doi:10.1007/s11427-004-0018-0

Okamoto O, Fujiwara S, Abe M, Sato Y. Dermatopontin interacts with MMP13 expression in human chondrocytes via DKK1 mediated canonical Wnt signaling inhibition. Osteoarthritis Cartilage. 2014;22:566-77. doi:10.1016/j.joca.2014.02.004
with transforming growth factor beta and enhances its biological activity. Biochem J. 1999;337:537-41. Medline:9895299 doi:10.1042/bj3370357

40 Grgurevic L, Macke B, Healy DR, Brautl AL, Erjavec I, Cipcic A, et al. Circulating bone morphogenetic protein-1 isoform increases renal fibrosis. J Am Soc Nephrol. 2011;22:681-92. Medline:21415150 doi:10.1681/ASN.2010070722

41 Lichtman MK, Otero-Vinas M, Falanga V. Transforming growth factor beta (TGF-β) isoforms in wound healing and fibrosis. Wound Repair Regen. 2016;24:215-22. Medline:26704519 doi:10.1111/wrr.12398

42 Ye C, Hou W, Chen M, Lu J, Chen E, Tang L, et al. IGFBP7 acts as a negative regulator of RANKL-induced osteoclastogenesis and oestrogen deficiency-induced bone loss. Cell Prolif. 2020;53:e12752. Medline:31889368 doi:10.1111/cpr.12752

43 Eguchi K, Akiba Y, Akiba N, Nagasawa M, Cooper LF, Uoshiba K. Insulin-like growth factor binding Protein-3 suppresses osteoblast differentiation via bone morphogenetic protein-2. Biochem Biophys Res Commun. 2018;507:465-70. Medline:30454898 doi:10.1016/j.bbrc.2018.11.065

44 Grgurevic L, Macke B, Mercep M, Jelic M, Smoljanovic T, Erjavec I, et al. Bone morphogenetic protein (BMP)-3 enhances bone repair. Biochem Biophys Res Commun. 2011;408:25-31. Medline:21453682 doi:10.1016/j.bbrc.2011.03.109

45 Salazar VS, Gamer LW, Rosen V. BMP signalling in skeletal development, disease and repair. Nat Rev Endocrinol. 2016;12:203-21. Medline:26893264 doi:10.1038/nrendo.2016.12

46 Yuan Y, Tan H, Dai P. Krüppel-like factor 2 regulates degradation of type II collagen by suppressing the expression of matrix metalloproteinases (MMP)-13. Cell Physiol Biochem. 2017;42:2159-68. Medline:28873368 doi:10.1159/000479991

47 Portinaro N, Case R, Gargan M. Pathological anatomy of developmental dysplasia of the hip joint. Hip Int. 2011;21:258-31. Medline:21453682 doi:10.1016/j.hipi.2011.03.109

48 Liu HK, Chua HH, Ooi GC, Lee KH. Proteaoglycan-4 as marker for chronic renal failure. Proteins. 2002;49:312-7. Medline:12145224 doi:10.1002/prot.10029

49 Verma P, Dalal K. ADAMTS-4 and ADAMTS-5: key enzymes in osteoarthritis. J Cell Physiol. 2004;201:1746-68. Medline:15548475 doi:10.1002/jcb.200400242

50 Savarino V, Savarino E. Magnetic resonance imaging of acetabular cartilage in children and adults. Radiographics. 2000;20:1229-45. Medline:10736150 doi:10.1148/rg.2020005202

51 Hanrioud B, Delépine M, Mascini P, Lenglet P, Macé A, Lespert J, et al. Genetic and clinical aspects of developmental dysplasia of the hip. J Pediatr. 2004;145:156-63. Medline:15218767 doi:10.1016/j.jpeds.2003.09.045

52 Martel-Pelletier J, Boileau C, Pelletier J-P. Cartilage in normal and osteoarthritis conditions. Best Pract Res Clin Rheumatol. 2008;22:351-84. Medline:18455690 doi:10.1016/j.berh.2008.02.001

53 Yamaguchi R, Yamamoto T, Motomura G, Ikekura S, Iwasaki K, Zhao G, et al. Bone and cartilage metabolism markers in synovial fluid of the hip joint with secondary osteoarthritis. Rheumatology (Oxford). 2014;53:2191-5. Medline:24958906 doi:10.1093/rheumatology/keu253

54 Yang C-Y, Chanalaris A, Troeberg L. ADAMTS and ADAM metalloproteinases in osteoarthritis—looking beyond the ‘usual suspects’. Osteoarthritis Cartilage. 2017;25:1000-9. Medline:28216310 doi:10.1016/j.joca.2017.02.791

55 Gudmann N, Karsdal M. Type X collagen. In: Karsdal MA, leeming DJ, Henriksen K, Bay-Jensen AC, Nielsen SH, Bager CL, editors. Biochemistry of collagens, laminins and elastin. Elsevier; 2016. p. 73-6.

56 Grgurevic L, Vukicevic S. inventors; Genera, Istrazivanja d.o.o., assignee. Proteaoglycan-4 as marker for chronic renal failure. European Patent Office EP2455755. 2012 May 23.

57 Schröder A, Schmitz-Ingber S. 'usual suspects' . Osteoarthritis Cartilage. 2017;25:1000-9. Medline:28216310 doi:10.1016/j.joca.2017.02.791

58 Grgurevic I, Macek B, Mercep M, Jelic M, Smoljanovic T, Erjavec I, et al. Bone morphogenetic protein (BMP)-3 enhances bone repair. Biochem Biophys Res Commun. 2011;408:25-31. Medline:21453682 doi:10.1016/j.bbrc.2011.03.109

59 Martel-Pelletier J, Boileau C, Pelletier J-P. Cartilage in normal and osteoarthritis conditions. Best Pract Res Clin Rheumatol. 2008;22:351-84. Medline:18455690 doi:10.1016/j.berh.2008.02.001

60 Karsdal MA, leeming DJ, Henriksen K, Bay-Jensen AC, Nielsen SH, Bager CL, editors. Procollagens, laminins and elastins. Elsevier; 2016. p. 73-6.

61 Grgurevic L, Vukicevic S. Osteoarthritis cartilage NSAIDs, proinflammatory cytokines and cartilage degradation. Osteoarthritis Cartilage. 2001;9:539-52. Medline:11520168 doi:10.1053/joca.2001.0427

62 Martel-Pelletier J, Boileau C, Pelletier J-P. Cartilage in normal and osteoarthritis conditions. Best Pract Res Clin Rheumatol. 2008;22:351-84. Medline:18455690 doi:10.1016/j.berh.2008.02.001

63 Grgurevic L, Vukicevic S. Osteoarthritis cartilage NSAIDs, proinflammatory cytokines and cartilage degradation. Osteoarthritis Cartilage. 2001;9:539-52. Medline:11520168 doi:10.1053/joca.2001.0427

64 Karsdal MA, leeming DJ, Henriksen K, Bay-Jensen AC, Nielsen SH, Bager CL, editors. Procollagens, laminins and elastins. Elsevier; 2016. p. 73-6.

65 Grgurevic L, Vukicevic S. Osteoarthritis cartilage NSAIDs, proinflammatory cytokines and cartilage degradation. Osteoarthritis Cartilage. 2001;9:539-52. Medline:11520168 doi:10.1053/joca.2001.0427

66 Karsdal MA, leeming DJ, Henriksen K, Bay-Jensen AC, Nielsen SH, Bager CL, editors. Procollagens, laminins and elastins. Elsevier; 2016. p. 73-6.

67 Grgurevic L, Vukicevic S. Osteoarthritis cartilage NSAIDs, proinflammatory cytokines and cartilage degradation. Osteoarthritis Cartilage. 2001;9:539-52. Medline:11520168 doi:10.1053/joca.2001.0427

68 Karsdal MA, leeming DJ, Henriksen K, Bay-Jensen AC, Nielsen SH, Bager CL, editors. Procollagens, laminins and elastins. Elsevier; 2016. p. 73-6.
65 Ashwell ZR, Flug J, Chadayammuri V, Pascual-Garrido C, Garabekyan T, Mei-Dan O. Lateral acetabular coverage as a predictor of femoroacetabular cartilage thickness. J Hip Preserv Surg. 2016;3:262-9. Medline:2633114 doi:10.1097/MD.0000000000014054

66 Nishii T, Shiomi T, Tanaka H, Yamazaki Y, Murase K, Sugano N. Loaded cartilage T2 mapping in patients with hip dysplasia. Radiology. 2010;256:955-65. Medline:2072007 doi:10.1148/radiol.10091924

67 Jessel RH, Zurakowski D, Zilkens C, Burstein D, Gray ML, Kim Y-J. Radiographic and patient factors associated with pre-radiographic osteoarthritis in hip dysplasia. J Bone Joint Surg Am. 2009;91:1120-9. Medline:19411140 doi:10.2106/JBJS.G.00144

68 Kim Y-J, Jaramillo D, Millis MB, Gray ML, Burstein D. Assessment of early osteoarthritis in hip dysplasia with delayed gadolinium-enhanced magnetic resonance imaging of cartilage. J Bone Joint Surg Am. 2003;85:1987-92. Medline:14563809 doi:10.1097/00004623-200310000-00019

69 Fuji M, Nakashima Y, Jingushi S, Yamamoto T, Noguchi Y, Suenaga E, et al. Intraarticular findings in symptomatic developmental dysplasia of the hip. J Pediatr Orthop. 2009;29:9-13. Medline:19098637 doi:10.1097/BPO.0b013e318190a0be

70 McCarthy JC, Lee J-A. Acetabular dysplasia: a paradigm of arthroscopic examination of chondral injuries. Clin Orthop Relat Res. 2002(405):122-8. Medline:12461363 doi:10.1097/00003086-200212000-00014

71 James S, Miocevic M, Malara F, Pike J, Young D, Connell D. MR imaging findings of acetabular dysplasia in adults. Skeletal Radiol. 2006;35:378-84. Medline:16570172 doi:10.1007/s00256-006-0082-8

72 Nishii T, Tanaka H, Sugano N, Sakai T, Hananouchi T, Yoshikawa H. Evaluation of cartilage matrix disorders by T2 relaxation time in patients with hip dysplasia. Osteoarthritis Cartilage. 2008;16:227-33. Medline:17644363 doi:10.1016/j.joca.2007.06.003

73 Domayer S, Mamisch TC, Kress I, Chan J, Kim Y. Radial dGEMRIC in developmental dysplasia of the hip and in femoroacetabular impingement: preliminary results. Osteoarthritis Cartilage. 2010;18:1421-8. Medline:20727414 doi:10.1016/j.joca.2010.08.010

74 Kawabe K, Konishi N. Three-dimensional modeling of cartilage thickness in hip dysplasia. Clin Orthop Relat Res. 1993;289:180-5. Medline:8472411

75 Xu L, Su Y, Kienle K-P, Hayashi D, Guermazi A, Zhang J, et al. Evaluation of radial distribution of cartilage degeneration and necessity of pre-contrast measurements using radial dGEMRIC in adults with acetabular dysplasia. BMC Musculoskelet Disord. 2012;13:212. Medline:23110607 doi:10.1186/1471-2474-13-212

76 Stelzeneder D, Mamisch T, Kress I, Domayer S, Werlen S, Bixby S, et al. Patterns of joint damage seen on MRI in early hip osteoarthritis due to structural hip deformities. Osteoarthritis Cartilage. 2012;20:661-9. Medline:22469848 doi:10.1016/j.joca.2012.03.014

77 Hingsammer A, Chan J, Kalish LA, Mamisch TC, Kim Y-J. Is the damage of cartilage a global or localized phenomenon in hip dysplasia, measured by dGEMRIC? Clin Orthop Relat Res. 2013;471:301-7. Medline:23079789 doi:10.1007/s11999-012-2633-8